Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells. Issue 4 (4th February 2015)

• Record Type: Journal Article
• Authors: Mao, Yan; Zhang, Yuzi; Qu, Qing; Zhao, Meizhong; Lou, Ying; Liu, Junjun; huang, Ou; Chen, Xiaosong; Wu, Jiayi; Shen, Kunwei
• Is Part Of: Molecular bioSystems. Volume 11:Issue 4(2015:Apr.)
• Page Start: 1029
• Page End: 1040
• Publication Date: 2015-02-04
• Subjects: Molecular biology -- Periodicals; Biochemistry -- Periodicals; 571.7405
• DOI: 10.1039/c4mb00710g
• Languages: English
• ISSNs: 1742-206X

Abstract

Abstract : CAFs isolated from HER2+ patients secreted higher levels of IL6 which expanded cancer stem cells and activated multiple pathways, then induced trastuzumab resistance in HER2 positive breast cancer cells. Abstract : Whether and how cancer-associated fibroblasts induce trastuzumab resistance in HER2+ breast cancer is still elusive. We analyzed the percentage of cancer stem cells and multiple pathway status before and after trastuzumab treatment in HER2 positive breast cancer cells co-cultured with conditional medium (CM) from CAFs. The results suggest that CAFs induce trastuzumab resistance by expanding cancer stem cells and activating multiple pathways, such as NF-κB, JAK/STAT3 and PI3K/AKT; combination of an anti-IL6 antibody, or multiple pathway inhibitors with trastuzumab in HER2 positive breast cancer maybe a novel strategy to reverse trastuzumab resistance.